Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)
- 31 January 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Rheumatology
- Vol. 2 (3), e153-e163
- https://doi.org/10.1016/s2665-9913(19)30160-2
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjögren's Syndrome: A Pilot StudyArthritis Care & Research, 2013
- Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusionsArthritis & Rheumatism, 2012
- Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximabAnnals Of The Rheumatic Diseases, 2012
- EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- A Simplified Quantitative Method for Assessing Keratoconjunctivitis Sicca From the Sjögren's Syndrome International RegistryAmerican Journal of Ophthalmology, 2009
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Health-related quality of life, employment and disability in patients with Sjögren's syndromeRheumatology, 2009
- Variability of flow rate when collecting stimulated human parotid salivaEuropean Journal of Oral Sciences, 2005
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002